RetromanIE
11-07-2011, 22:24
<img alt="" height="1" width="1" />
Novartis' Votubia reduces benign brain tumours in SEGA patients (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHjrZUsRymb67XejXrrLlG5IV_Wgw&url=http://www.inpharm.com/news/162000/novartis-votubia-reduces-benign-brain-tumours-sega-patients)
InPharm
Novartis' novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus – and also branded as Afinitor) helped more than a third of patients over three years old reduce the size of their subependymal ...
Novartis Presents Afinitor Data (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFdGLdXKupaGC3o0WFBHYzN0jA0yQ&url=http://www.zacks.com/stock/news/56746/Novartis%2BPresents%2BAfinitor%2BData)Zacks.com
Phase III trial of Novartis drug Afinitor met primary endpoint of reducing ... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGYu91Z1gab9EAq-cs4VpT8cvk7WQ&url=http://www.pharmabiz.com/NewsDetails.aspx?aid%3D63883%26sid%3D2)pharmabiz.c om
Novartis' Afinitor meets primary endpoint in Ph III SEGAs brain tumor study (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEo6I-5JgwXFuEo2-bm0WF3GJydbg&url=http://www.thepharmaletter.com/file/105683/novartis-afinitor-meets-primary-endpoint-in-ph-iii-segas-brain-tumor-study.html)The Pharma Letter (subscription)
all 5 news articles » (http://news.google.ie/news/more?pz=1&ned=en_ie&ncl=dDN140HTEO-o7oMSXDc_BJfTvXJpM)
More... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHjrZUsRymb67XejXrrLlG5IV_Wgw&url=http://www.inpharm.com/news/162000/novartis-votubia-reduces-benign-brain-tumours-sega-patients)
Novartis' Votubia reduces benign brain tumours in SEGA patients (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHjrZUsRymb67XejXrrLlG5IV_Wgw&url=http://www.inpharm.com/news/162000/novartis-votubia-reduces-benign-brain-tumours-sega-patients)
InPharm
Novartis' novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus – and also branded as Afinitor) helped more than a third of patients over three years old reduce the size of their subependymal ...
Novartis Presents Afinitor Data (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFdGLdXKupaGC3o0WFBHYzN0jA0yQ&url=http://www.zacks.com/stock/news/56746/Novartis%2BPresents%2BAfinitor%2BData)Zacks.com
Phase III trial of Novartis drug Afinitor met primary endpoint of reducing ... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGYu91Z1gab9EAq-cs4VpT8cvk7WQ&url=http://www.pharmabiz.com/NewsDetails.aspx?aid%3D63883%26sid%3D2)pharmabiz.c om
Novartis' Afinitor meets primary endpoint in Ph III SEGAs brain tumor study (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEo6I-5JgwXFuEo2-bm0WF3GJydbg&url=http://www.thepharmaletter.com/file/105683/novartis-afinitor-meets-primary-endpoint-in-ph-iii-segas-brain-tumor-study.html)The Pharma Letter (subscription)
all 5 news articles » (http://news.google.ie/news/more?pz=1&ned=en_ie&ncl=dDN140HTEO-o7oMSXDc_BJfTvXJpM)
More... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHjrZUsRymb67XejXrrLlG5IV_Wgw&url=http://www.inpharm.com/news/162000/novartis-votubia-reduces-benign-brain-tumours-sega-patients)